Background: Papillary thyroid carcinoma (PTC) is the commonest thyroid cancer. Cases in category5a of Bethesda system (suspicious for papillary carcinoma) are treated by surgical lobectomy followed by total thyroidectomy if histopathology confirms papillary carcinoma. In order to reduce surgical procedures to one this was conducted. Objectives: evaluation of role of immunohistochemistry in pre-operative diagnosis of papillary thyroid carcinoma on cell blocks. Materials and Method: Cell blocks were taken from cases labelled category-5a for histopathology and immunohistochemistry using three markers (CK-19, Thyro-peroxidase, and BRAF v600E mutation). Results: were highly sensitive, and specific. The use of more than markers increases sensitivity of the procedure. Conclusion: immunohistochemical stains on cell blocks is a reliable method for pre-operative diagnosis of papillary thyroid carcinoma.
Introduction:
Papillary thyroid carcinoma (PTC) is the commonest malignant thyroid tumor constituting 83% of thyroid cancer [1] . Clinical and sonographic suspicious thyroid nodules are managed by fine needle aspiration cytopathology (FNAC) [2, 3] . In order to unify terminology and increases communication between pathologists and clinicians Bethesda system for reporting thyroid cytopathology was introduced [4, 5] . It includes six categories, with approximate percentage of occurrence, risk of malignancy of each category and suggested management, table-1. Category-4a includes cases suspicious of papillary thyroid carcinoma. These cases are treated by lobectomy and followed by total thyroidectomy if histopathology confirm papillary thyroid carcinoma. Two stages operation will have a burden on health and financial state of patients. In order to overcome this problem, the current study was designed for preoperative confirmation or exclusion of papillary thyroid carcinoma using three immunohistochemical markers (Cytokeratin-19, Thyro-peroxidase and BRAF V600E). They are applied on cell blocks taken from FNAC in order to reduce the number of two stages surgery. Cytokeratin-19 (CK19) is present in most cells of papillary thyroid carcinoma. It has a low molecular weight and present in basal cell and epithelium [6, 7] . Thyro-peroxidase (TPO) is an enzyme essential in thyroid function and iodine metabolism. It is present in normal and benign thyroid tissues but negative in papillary thyroid carcinoma [6, 8] . The common genetic mutation in papillary thyroid carcinoma is (BRAF) gene ). This mutation is not seen in benign or other malignant thyroid lesions [9, 10] . Immunohistochemical findings on cell blocks: Cytokeratin-19 (CK-19) was positive in 50 cases of papillary thyroid carcinoma (86.21%) and negative in 8 (13.79%). CK-19 is negative in all benign thyroid lesions. Thyro-peroxidase (TPO) was negative 46 cases of PTC (79.31%) and positive in 12 (20.69%). PTO was positive in all benign cases. BRAF v600E mutation was positive in 52 (89.66%), negative in 6 (10.34%) cases of PTC, and negative in all benign thyroid conditions. Employing all three markers together 56 (96.55%) were positive and 2 (3.45%) were negative figure-2. 
Discussion
The histopathology results of resected specimens were considered as a gold standard method for diagnosis, i.e. cases with papillary carcinoma are considered as papillary carcinoma and benign cases are benign despite the results of IHC. Histopathology on resected specimens from cases of category-5a (suspicious for papillary carcinoma) showed papillary thyroid carcinoma and benign conditions in 63.04% and 36.96% respectively. This coincides with risk of carcinoma in category-5a of Bethesda system, and with other international studies [3, 4, 5]. Present work showed the studied markers were perfectly stained in cell blocks taken from FNAC of thyroid. On IHC, CK-19 was positive in 50/58 (86.21%), negative in 8/58(13.79%) cases of papillary thyroid carcinoma (PTC). CK-19 was negative in all benign thyroid cases (no false positive results seen). The sensitivity and specificity of CK-19 in diagnosis of PTC were 86.21% and 100% respectively. These findings are in agreement with studies by Hemanathan Guhanandam et al and Haiyan Liu et al [6, 7] . Thyro-peroxidase (TPO) is present in normal and benign thyroid tissues but negative in most cases of papillary thyroid carcinoma [7, 8] . In current study it was negative in 46/58 (79.31%), positive in 12/58 (20.69%) of PTC cases diagnosed by histopathology. The TPO was positive in all benign cases (no false positive results). The sensitivity and specificity of TPO were 79.31%, and 100% respectively. The IHC findings of TPO were also in agreement with other international studies by Liu Z et al [12] , and Lihua Huang [13] . BRAF v600E mutation by IHC was positive in 52 (89.66%), negative in 6 (10.34%) of cases of thyroid papillary carcinoma, and it is also negative in all benign thyroid conditions. The sensitivity and specificity of BRAF v600E in papillary thyroid carcinoma approaching 89.66%, and 100% respectively. There is no positive mutation of BRAF v600E in all benign conditions (there is no false positive results). Results of BRAF v600E mutation in the current study is consisting with other internal studies by Najla Fakhruddin et al [14] , and Efisio Puxeddu et al [15] . The sensitivity and specificity of the three markers together by IHC (CK-19, TPO, and BRAF v600E ) were 96.55%, and 100% respectively.
Conclusion:
Any thyroid lesion positive for CK-19, BRAF v600E , and/or negative for TPO is considered as a thyroid papillary carcinoma and the use of more than one marker increases the sensitivity of the procedure. 
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